Skip to content

Outcomes of Liver Transplantation in Low Weight Children After Reducing the Lateral Segment of a Living Donor, Adapting the Shape and Size of the Graft to the Needs of the Recipient

Short and Long-term Outcomes After Transplantation With Hyper-reduced Liver Grafts in Low-Weight Pediatric Recipients

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03594864
Enrollment
58
Registered
2018-07-20
Start date
2018-04-21
Completion date
2018-06-03
Last updated
2018-07-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyper-reduced Liver Grafts, Liver Transplantation, Low-weight Children

Keywords

Liver, Transplantation, Hyper-reduction, Graft survival, Overall survival

Brief summary

The shortage of organs has always been a problem in pediatric liver transplants due to the lack of donors with an adequate size. Different techniques of hepatic reduction have been described that allow to use larger organs in the pediatric population. However, in these techniques the maximum reduction achieved by segments 2 and 3 is excessive for low-weight children. Since 1997 the liver transplantation group at Hospital Italiano de Buenos Aires has developed and practiced a technique called hepatic hyper-reduction, which consists in reducing the lateral segment of a living donor, adapting the shape and size of the graft to the needs of the recipient. The investigators have performed approximately 50 pediatric liver transplants with live donors in low weight children in whom the hyper-reduction technique has been applied. The aim of the present study is to describe postoperative morbidity and mortality and analyze overall and graft survival.

Interventions

PROCEDURELiver transplantation with hyper-reduced grafts

Live donor liver transplantation using non-anatomical in-situ ultrasound-guided reduction of left lateral segments with preparation of a graft that is larger than a monosegment, but smaller than Segments 2 and 3.

Sponsors

Hospital Italiano de Buenos Aires
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
5 Months to 17 Years
Healthy volunteers
No

Inclusion criteria

* \< or = 17 years old. * Having undergone live donor liver transplantation. * Having received hyper-reduced liver grafts * At the Liver Transplantation Unit of the Hospital Italiano de Buenos Aires * Between June 1997 and April 2018

Exclusion criteria

* \> 17 years old. * Cadaveric liver transplant * Whole liver grafts.

Design outcomes

Primary

MeasureTime frameDescription
Overall survival at 1 year.Overall survival wil be reported at 1 year after liver transplantation.Overall survival was defined as the time from surgery to death (all causes) or date of last follow-up, measured in months.
Overall survival at 3 years.Overall survival wil be reported at 3 years after liver transplantation.Overall survival was defined as the time from surgery to death (all causes) or date of last follow-up, measured in months.
Overall survival at 10 years.Overall survival wil be reported at 10 years after liver transplantation.Overall survival was defined as the time from surgery to death (all causes) or date of last follow-up, measured in months.
Graft survival at 1 year.Graft survival wil be reported at 1 year after liver transplantation.Graft survival was defined as the time from surgery to the date of re-transplantation or re-entry to waiting list, measured in months.
Graft survival at 3 years.Graft survival wil be reported at 3 years after liver transplantation.Graft survival was defined as the time from surgery to the date of re-transplantation or re-entry to waiting list, measured in months.
Graft survival at 10 years.Graft survival wil be reported at 10 years after liver transplantation.Graft survival was defined as the time from surgery to the date of re-transplantation or re-entry to waiting list, measured in months.

Countries

Argentina

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026